Euroopa Liit - eesti - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Eesti - eesti - Ravimiamet

jsc olainfarm - omeprasool - gastroresistentne kõvakapsel - 10mg 140tk; 10mg 60tk; 10mg 15tk; 10mg 500tk; 10mg 56tk; 10mg 50tk; 10mg 100tk; 10mg 28tk

Eesti - eesti - Ravimiamet

jsc olainfarm - omeprasool - gastroresistentne kõvakapsel - 20mg 60tk; 20mg 7tk; 20mg 140tk; 20mg 56tk; 20mg 100tk; 20mg 14tk; 20mg 50tk; 20mg 280tk

Eesti - eesti - Ravimiamet

jsc olainfarm - omeprasool - gastroresistentne kõvakapsel - 40mg 28tk; 40mg 14tk; 40mg 15tk; 40mg 56tk; 40mg 30tk; 40mg 5tk; 40mg 50tk; 40mg 7tk; 40mg 500tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - immunoloogilised vahendid - sheep; cattle - sheepactive vaktsineerimine lammaste katarraalse palaviku viiruse serotüüp 8 vältimiseks viraemia ja vähendada kliinilisi tunnuseid. algusega immuunsus: 20 päeva pärast teist annust. kestus immuunsus: 1 aasta pärast teise annuse. cattleactive vaktsineerimine lammaste katarraalse palaviku viiruse serotüüp 8 vältimiseks viraemia. immuunsuse tekkimine: 31 päeva pärast teist annust. kestus immuunsus: 1 aasta pärast teise annuse.

Eesti - eesti - Ravimiamet

berlin-chemie ag - ibuprofeen - suukaudne suspensioon - 40mg 1ml 150ml 1tk; 40mg 1ml 30ml 1tk; 40mg 1ml 200ml 1tk; 40mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - ibuprofeen - suukaudne suspensioon - 40mg 1ml 150ml 1tk; 40mg 1ml 30ml 1tk; 40mg 1ml 100ml 1tk

Eesti - eesti - Ravimiamet

nutra essential otc s.l. - ibuprofeen - suukaudne suspensioon - 20mg 1ml 200ml 1tk

Eesti - eesti - Ravimiamet

pfizer europe ma eeig - piroksikaam - geel - 0,5% 25g 1tk

Eesti - eesti - Ravimiamet

viatris healthcare limited - kodeiin+ibuprofeen - õhukese polümeerikattega tablett - 30mg+400mg 30tk